Acer Therapeutics announced that it has signed an exclusive license agreement with Sanofi to acquire worldwide rights to osanetant, a clinical-stage, non-peptide tachykinin NK3 receptor antagonist. Acer said in a statement that it plans to initially pursue development of osanetant as a potential treatment for certain neuroendocrine-related disorders. Financial terms of the license agreement were not unveiled.